Authors

Jaideep Shenoi, MD

Latest:

The Art of Analogies in the Clinic

Translating medical nomenclature into language that is easily understood by patients can be difficult.

Jake Gibson

Latest:

Ars Medica: Soothing cancer patients through art therapy

Before Western medicine took root, therapies often tapped both the mind and body to promote healing.

Jake Micallef, PhD

Latest:

Dr. Micallef on NuQ Blood Tests in Prostate Cancer

Jake Micallef, PhD, chief scientific officer, VolitionRX, discusses the science of the NuQ biomarker assay as a detection tool for early-stage prostate cancer.

Jalid Sehouli, MD

Latest:

Dr. Sehouli Discusses Unmet Needs in Ovarian Cancer

Jalid Sehouli, MD, professor, director of the Clinic Campus Virchow and Campus Benjamin Franklin Charité Center Gynecology, Charité – Universitatsmedizin Berlin, discusses the unmet needs for patients with ovarian cancer.

Jame Abraham, MD

Latest:

Sharing the Latest in Breast Cancer Care With Drs Rena Callahan and Jame Abraham

Jame Abraham, MD, of Cleveland Clinic, and Rena D. Callahan, MD, of UCLA, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.

Jame Abraham, MD, FACP

Latest:

Achieving Career Success in Academic Oncology

Academic oncologists have a critical role as opinion leaders and shape the future of cancer care by research and training future oncologists, residents, and medical students.

James A. Jorgenson, RPh, MS

Latest:

Specialty Pharmacy: Status and Future Direction

When talking about specialty pharmacy, I am reminded of the famous words of Supreme Court Justice Potter Stewart as he ruled on a 1964 obscenity case.

James A. Trovato, PharmD, MBA, BCOP

Latest:

Racial/Ethnic and Age Disparities in Chemotherapy Selection for Colorectal Cancer

Studies have evaluated racial/ethnic and age disparities in whether patients receive chemotherapy for nonmetastatic colo-rectal cancer

James B. Bussel, MD, NewYork-Presbyterian/Weill Cornell Medical Center

James B. Yu, MD

Latest:

Dr Yu discusses the ARCAD Nomogram in a Real-World CRC Population

James Yu, MD, discusses the validation of the ARCAD nomogram in the real-world setting for patients with stage IV colorectal cancer.

James Battiste, MD, PhD

Latest:

Dr. Battiste on Biomarkers in Glioblastoma

James Battiste, MD, PhD, assistant professor at the University of Oklahoma department of neurology and researcher at Stephenson Cancer Center, discusses research in glioblastoma (GBM).

James Blachly, MD

Latest:

MRD Testing and the Role of Revumenib in Treatment Response

Panelists discuss the role of minimal residual disease (MRD) testing in acute monocytic leukemia (AML), key findings from the Australasian Leukaemia and Lymphoma Group (ALLG) AMLM26 INTERCEPT study on revumenib, and how the efficacy of revumenib in achieving MRD negativity in NPM1-mutated AML informs future MRD-guided treatment strategies, including the potential integration of menin inhibitors into standard AML relapse prevention protocols.

James C. Salwitz, MD

Latest:

Oncologists and Hospice

Oncologists need to learn that it is possible, and indeed preferable, to have very early discussions about end-of-life choice.

James C. Yang, MD

Latest:

Dr. Yang Discusses the Future of Lung Cancer Treatment

James CH Yang, MD, PhD, from the National Taiwan University Hospital, discusses the future of lung cancer treatment.

James C. Yao, MD

Latest:

Dr. Yao on Health-Related QOL in Patients With Neuroendocrine Tumors

James C. Yao, MD, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, discusses a study exploring health-related quality of life (QOL) in patients with neuroendocrine tumors (NETs).

James C. Yao, MD, MD Anderson

James C. Yao, MD, The University of Texas MD Anderson Cancer Center

James C. Yao, MD, University of Texas MD Anderson

James C. Yao, MD, University of Texas MD Anderson Cancer Center

James CH Yang, MD

Latest:

Dr. Yang on Resistance Mechanisms from Osimertinib in NSCLC

James CH Yang, MD, PhD, Professor of Medicine, Deputy Director, Department of Medical Oncology, National Taiwan University Hospital, Director, Cancer Research, Center National Taiwan University College of Medicine, discusses resistance mechanisms that develop from treatment with osimertinib (Tagrisso) and other EGFR tyrosine kinase inhibitors (TKIs). Yang discussed this in an interview during the 2018 European Lung Cancer Congress, which is a joint collaboration between ESMO and the IASLC.